Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder‐relapser hepatitis C patients: a prospective multicentre randomized controlled study

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Viral Hepatitis

• Publication date

  2003-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2893.2003.00426.xPMID 12753341
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

  2002cited by this paper
• Comparative Effects of Different Doses of Ribavirin Plus Interferon-α2b for Therapy of Chronic Hepatitis C: Results of a Controlled, Randomized Trial

  2001cited by this paper
• A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

  2001cited by this paper
• Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy

  2000cited by this paper
• Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• Retreatment for 24 vs 48 weeks with interferon‐α2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone

  2000cited by this paper
• PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• Neuropsychiatric Toxicity of Antiviral Treatment in Chronic Hepatitis C

  2000cited by this paper
• Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy

  1999cited by this paper
• Possible association between serum GB virus C RNA level and disease activity in fulminant hepatitis type G.

  1999cited by this paper
• Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

  1999cited by this paper
• Chronic hepatitis C: Interferon retreatment of relapsers. A meta‐analysis of individual patient data

  1999cited by this paper
• Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials

  1999cited by this paper
• A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group.

  1999cited by this paper
• A short induction regimen of interferon‐α is not effective for treatment of relapse in chronic hepatitis C: a randomized trial

  1999cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• Multicenter Evaluation of the COBAS AMPLICOR HCV Assay, an Integrated PCR System for Rapid Detection of Hepatitis C Virus RNA in the Diagnostic Laboratory

  1998cited by this paper
• The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses.

  1998cited by this paper
• Better efficacy of a 12‐month interferon alfa‐2b retreatment in patients with chronic hepatitis C relapsing after a 6‐month treatment: A multicenter, controlled, randomized trial

  1998cited by this paper
• Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

  1996cited by this paper
• Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C

  1995cited by this paper
• Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients

  1995cited by this paper
• Variability of hepatitis C virus

  1995cited by this paper
• A proposed system for the nomenclature of hepatitis C viral genotypes

  1994cited by this paper
• Suicide associated with alfa-interferon therapy for chronic viral hepatitis.

  1994cited by this paper
• Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

  1981cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• A statistical method for removing unbalanced trials with multiple covariates in meta-analysis

  2023cites this paper
• Ribavirin plus interferon versus interferon for chronic hepatitis C.

  2010cites this paper
• Ribavirin plus interferon versus interferon for chronic hepatitis C.

  2010cites this paper
• Progress in hepatitis C genotyping and its clinical significance

  2009cites this paper
• Treatment of relapsers after combination therapy for chronic hepatitis C.

  2006cites this paper
• Effect of interferon alfa and ribavirin treatment on hepatitis C virus RNA in serum and peripheral blood mononuclear cells in children with chronic hepatitis C.

  2006cites this paper
• Treatment of relapsers after combination therapy for chronic hepatitis C.

  2004cites this paper
• Prediction of treatment outcome with daily high-dose IFN alpha-2b plus ribavirin in patients with chronic hepatitis C with genotype 1b and high HCV RNA levels: relationship of baseline viral levels and viral dynamics during and after therapy.

  2004cites this paper